Search results
Results from the WOW.Com Content Network
Alcohol-related dementia can produce a variety of psychiatric problems including psychosis (disconnection from reality), depression, anxiety, and personality changes. Patients with alcoholic dementia often develop apathy, related to frontal lobe damage, that may mimic depression. [3] People with an alcohol use disorder are more likely to become ...
Alcohol abuse affects neurons in the frontal cortex that typically have a large soma, or cell body. This type of neuron is more susceptible to Alzheimer's disease and normal aging. Research is still being conducted to determine whether there is a direct link between excessive alcohol consumption and Alzheimer's disease. [8]
Alcoholism shares a robust relationship with dementia risk, and the correlative literature is getting stronger by the decade.. As of 2020, Alcohol-related brain damage (ARBD) is studied to affect ...
Hashimoto's encephalopathy, also known as steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT), is a neurological condition characterized by encephalopathy, thyroid autoimmunity, and good clinical response to corticosteroids. It is associated with Hashimoto's thyroiditis, and was first described in 1966.
Hashimoto's thyroiditis, also known as chronic lymphocytic thyroiditis and Hashimoto's disease, is an autoimmune disease in which the thyroid gland is gradually destroyed. [1][6] A slightly broader term is autoimmune thyroiditis, identical other than that it is also used to describe a similar condition without a goiter. [7][8] Early on ...
Leqembi’s side effects and other potential issues. Leqembi offers doctors the first new Alzheimer’s treatment option in years. But it also has some possibly dangerous side effects. Those ...
The Nun Study of Aging and Alzheimer's Disease is a continuing longitudinal study, begun in 1986, to examine the onset of Alzheimer's disease. [1] [2] David Snowdon, an Epidemiologist and the founding Nun Study investigator, started the Nun Study at the University of Minnesota, later transferring the study to the University of Kentucky in 1990. [3]
The agency’s approval was based on a late-stage clinical trial of 1,700 people that showed the drug slowed the progression of Alzheimer’s by about 35% after 18 months, compared to a placebo ...